We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) announced positive top-line data from a late-stage study evaluating a chemotherapy-free regimen of its drug, Rybrevant (amivantamab-vmjw), for treating EGFR-mutated first-line non-small cell lung cancer (NSCLC).
The phase III MARIPOSA study evaluated Rybrevant in combination with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), versus AstraZeneca’s (AZN - Free Report) Tagrisso (osimertinib) as a first-line treatment in EGFR-mutated NSCLC. Tagrisso is AZN’s third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC.
AstraZeneca received the FDA approval for Tagrisso in March 2017 for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, whose disease has progressed on or after EGFR TKI therapy.
JNJ’s Rybrevant is currently approved for the treatment of adult patients with locally advanced or metastatic NSCLC, whose disease has progressed on or after platinum-based chemotherapy.
The MARIPOSA study met its primary endpoint of progression-free survival (PFS) in patients receiving Rybrevant plus lazertinib compared with AZN’s Tagrisso, demonstrating statistical significance and clinically meaningful improvement.
Furthermore, an interim analysis of the overall survival (OS), one of the secondary endpoints of the study, also favored the treatment arm receiving the combination therapy of Rybrevant and lazertinib compared with Tagrisso. However, the statistical and clinical significance of OS data has not been determined yet.
Other secondary endpoints in the MARIPOSA study include objective response rate, duration of response, intracranial PFS, PFS after first subsequent therapy and time to symptomatic progression.
The safety profile of the Rybrevant/lazertinib combo was also consistent with that observed in previously reported data of the combo drug.
Management claims that the current standard-of-care EFGR TKIs in the first-line treatment of EGFR-mutated NSCLC often lead to resistance and disease progression when used as monotherapy, representing a serious unmet medical need. The combination therapy of Rybrevant and lazertinib, subject to successful development, has the potential to advance treatment beyond TKI monotherapy in this indication.
The data readout from the MARIPOSA study marks the third late-stage study on Rybrevant to be announced in 2023, following results from the PAPILLON and MARIPOSA-2 studies.
JNJ plans to present results from MARIPOSA, PAPILLON and MARIPOSA-2 studies at an upcoming medical conference, which will include additional details on select secondary endpoints.
Johnson and Johnson is also currently evaluating Rybrevant in multiple other studies in NSCLC indication.
Currently, the standard of care in the frontline treatment of metastatic NSCLC is Merck’s (MRK - Free Report) Keytruda. Notably, Keytruda, an anti-PD-1 therapy, is MRK’s blockbuster oncology drug and approved for several types of cancer, accounting alone for around 40% of Merck’s pharmaceutical sales.
Keytruda is presently approved to treat seven indications in earlier-stage cancers in the United States. Keytruda is continuously growing and expanding into new indications and markets globally, bolstering Merck’s position in the oncology market.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study
Johnson & Johnson (JNJ - Free Report) announced positive top-line data from a late-stage study evaluating a chemotherapy-free regimen of its drug, Rybrevant (amivantamab-vmjw), for treating EGFR-mutated first-line non-small cell lung cancer (NSCLC).
The phase III MARIPOSA study evaluated Rybrevant in combination with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), versus AstraZeneca’s (AZN - Free Report) Tagrisso (osimertinib) as a first-line treatment in EGFR-mutated NSCLC. Tagrisso is AZN’s third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC.
AstraZeneca received the FDA approval for Tagrisso in March 2017 for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, whose disease has progressed on or after EGFR TKI therapy.
JNJ’s Rybrevant is currently approved for the treatment of adult patients with locally advanced or metastatic NSCLC, whose disease has progressed on or after platinum-based chemotherapy.
The MARIPOSA study met its primary endpoint of progression-free survival (PFS) in patients receiving Rybrevant plus lazertinib compared with AZN’s Tagrisso, demonstrating statistical significance and clinically meaningful improvement.
Furthermore, an interim analysis of the overall survival (OS), one of the secondary endpoints of the study, also favored the treatment arm receiving the combination therapy of Rybrevant and lazertinib compared with Tagrisso. However, the statistical and clinical significance of OS data has not been determined yet.
Other secondary endpoints in the MARIPOSA study include objective response rate, duration of response, intracranial PFS, PFS after first subsequent therapy and time to symptomatic progression.
The safety profile of the Rybrevant/lazertinib combo was also consistent with that observed in previously reported data of the combo drug.
Management claims that the current standard-of-care EFGR TKIs in the first-line treatment of EGFR-mutated NSCLC often lead to resistance and disease progression when used as monotherapy, representing a serious unmet medical need. The combination therapy of Rybrevant and lazertinib, subject to successful development, has the potential to advance treatment beyond TKI monotherapy in this indication.
The data readout from the MARIPOSA study marks the third late-stage study on Rybrevant to be announced in 2023, following results from the PAPILLON and MARIPOSA-2 studies.
JNJ plans to present results from MARIPOSA, PAPILLON and MARIPOSA-2 studies at an upcoming medical conference, which will include additional details on select secondary endpoints.
Johnson and Johnson is also currently evaluating Rybrevant in multiple other studies in NSCLC indication.
Currently, the standard of care in the frontline treatment of metastatic NSCLC is Merck’s (MRK - Free Report) Keytruda. Notably, Keytruda, an anti-PD-1 therapy, is MRK’s blockbuster oncology drug and approved for several types of cancer, accounting alone for around 40% of Merck’s pharmaceutical sales.
Keytruda is presently approved to treat seven indications in earlier-stage cancers in the United States. Keytruda is continuously growing and expanding into new indications and markets globally, bolstering Merck’s position in the oncology market.